|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
Vaccination Success Rate and Reaction Profile With Diluted and Undiluted Smallpox Vaccine
The stockpile of vaccines to treat patients in the event of a bioterror attack is currently quite limited. However, this study finds that the standard vaccine treatment for smallpox, the Aventis Pasteur smallpox vaccine (APSV), is still effective even at diluted doses; however, "reactogenicity was not reduced with dilution of the vaccine and, as with other smallpox vaccines, may impair daily activities." In other words, the diluted vaccine is effective, but it also still causes the adverse effects associated with an undiluted dose.
This is a welcome finding – since it multiplies the number of effective doses at our disposal in the event of an attack – but it is disquieting to think that we are still dependent on a smallpox vaccine that was developed 50 years ago using now-antiquated technology.
|home spotlight commentary research events news about contact links archives|